The federal contract IDV award W911SR22D0009 was issued by the Joint Program Executive Office for Chemical and Biological Defense, a Defense agency, to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The single-award Indefinite Delivery Contract has a ceiling value of $249,006,382.00 and is for the acquisition of FDA-approved products supporting chemical and biological defense programs. Associated task orders under the IDC advance the development and testing of a monoclonal antibody countermeasure through clinical trials and regulatory approval processes.
Resilience Government Services, a technology-focused biomanufacturing company, has previously conducted work for the Department of Defense and Department of Health and Human Services on medical countermeasure development, pharmaceutical manufacturing, and clinical trials. The current task orders, totaling $120,924,639.86, cover activities such as drug substance and drug product process validation, clinical development phase 2 and 3 studies, and storage/stability testing with the ultimate goal of obtaining U.S. FDA licensure for the BONT mAb G03-52-01 drug product. These task orders are not set aside and are associated with Resilience's two active Indefinite Delivery Vehicles from the Department of the Army's Acquisition Support Center.
Generated 12/9/24, 1:46 PM